• 2021 Year
    COVID-19 vaccine Convidecia, MCV2 and MCV4 received approval
  • 2020 Year
    Developed COVID-19 vaccine Convidecia; Successfully listed on STAR market of the Shanghai Stock Exchange
  • 2019 Year
    NDA for MCV2 was accepted by NMPA;
    Listed on the Main Boary of HKEx;
    NDA for MCV4 was granted with Priority Review designation
  • 2018 Year
    Completed commissioning of commercial manufacturing facility;
    CTA approved for DTcP and PBPV;
    Completed phase Ⅲ clinical trials for MCV2 and MCV4;
    Filed CTA for Pcv13i;
  • 2017 Year
    Obtained NDA approval of Ad5-EBOV in China
  • 2016 Year
    Completed Ad5-EBOV Phase II clinical trial in Sierra Leone;
    Submitted CTA of PBPV
  • 2015 Year
    Pilot facility passed EMA's QP inspection;
    Obtained MCV2 & MCV4 CTA approvals
  • 2014 Year
    Filed CTA for DTcP candidates;
    Obtained CTA approval of Ad5-EBOV and initiated clinical trial
  • 2013 Year
    Filed CTA for MCV2 & MCV4
  • 2012 Year
    Completed commissioning of pilot facility designed to meet the GMP
  • 2009 Year
    Incorporated and registered in Tianjin, China